688266.SHG Suzhou Zelgen Biopharmaceuticals Co Ltd
- Market cap
- CNY 24.1B
- P/E
- 42.6x
- P/B
- 12.87x
- ROE
- 49.5%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688266.SHG undervalued?
Graham numberThe Graham number of Suzhou Zelgen Biopharmaceuticals Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Suzhou Zelgen Biopharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Suzhou Zelgen Biopharmaceuticals Co Ltd yet.
Suzhou Zelgen Biopharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopec…
Full company profileSuzhou Zelgen Biopharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Suzhou Zelgen Biopharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 200K | 0.00 | 1.31M | 0.00 | 27.7M | 190M | 302M | 386M | 533M | 813M | 2.05B |
| Gross Profit | 4.53K | -238K | 82.6K | -176K | 27.1M | 183M | 275M | 355M | 495M | 813M | 1.91B |
| Operating Income | -134M | -146M | -443M | -440M | -305M | -459M | -486M | -298M | -155M | -166M | 849M |
| EBITDA | -123M | -142M | -434M | -406M | -269M | -417M | -421M | -233M | -83.0M | -123M | 869M |
| Net Income | -128M | -146M | -440M | -462M | -319M | -451M | -457M | -279M | -138M | -161M | 851M |
| EPS | -0.71 | -0.81 | -0.11 | -2.57 | -1.36 | -1.88 | -1.91 | -1.09 | -0.52 | -0.61 | 3.21 |
| Balance Sheet | |||||||||||
| Total Assets | 137M | 148M | 455M | 320M | 1.97B | 1.75B | 1.67B | 2.89B | 3.00B | 2.97B | 3.31B |
| Total Liabilities | 27.8M | 74.6M | 173M | 247M | 279M | 493M | 881M | 1.24B | 1.75B | 1.89B | 1.59B |
| Shareholders' Equity | 109M | 73.0M | 226M | 3.43M | 1.62B | 1.20B | 759M | 1.63B | 1.25B | 1.08B | 1.72B |
| Cash & Short-term Investments | 17.0M | 9.88M | 129M | 72.9M | 1.60B | 1.20B | 1.05B | 2.25B | 2.19B | 2.03B | 1.58B |
| Total Debt | - | - | 4.53M | 60.0M | 47.7M | 224M | 548M | 825M | 1.02B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -56.7M | -108M | -112M | -180M | -344M | -455M | -370M | -220M | 38.2M | -28.8M | - |
| Capital Expenditure | 24.3M | 11.7M | 11.1M | 15.1M | 57.7M | 70.7M | 88.6M | 62.6M | 95.7M | 181M | 96.7M |
| Free Cash Flow | -81.0M | -120M | -124M | -196M | -402M | -525M | -459M | -295M | -57.5M | -210M | 1.01B |
| Ratios | |||||||||||
| ROE | -117.2% | -200.6% | -194.5% | -13,480.9% | -19.7% | -37.7% | -60.2% | -17.1% | -11.0% | -14.9% | 49.5% |
| ROA | -93.5% | -99.2% | -96.7% | -144.2% | -16.2% | -25.8% | -27.4% | -9.6% | -4.6% | -5.4% | 25.7% |
| Net Profit Margin | -64,027.0% | - | -33,564.9% | - | -1,154.1% | -236.9% | -151.3% | -72.1% | -25.9% | -19.8% | 41.5% |
| Debt to Equity | - | - | 0.02x | 17.51x | 0.03x | 0.19x | 0.72x | 0.51x | 0.82x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Suzhou Zelgen Biopharmaceuticals Co Ltd dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 26.1M | 0.10 | - |
| 2024 | CNY 24.6M | 0.09 | - |
| 2023 | CNY 21.2M | 0.08 | - |
| 2022 | CNY 11.2M | 0.05 | - |
| 2021 | CNY 4.14M | 0.02 | - |
| 2020 | CNY 1.11M | 0.00 | - |
| 2019 | CNY 1.16M | 0.01 | - |
| 2018 | CNY 1.11M | 0.00 | - |
| 2017 | CNY 1.11M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Suzhou Zelgen Biopharmaceuticals Co Ltd
- Insiders 28.20%
- Institutions 29.11%
- Public & others 42.69%
- Shares outstanding 265M
- Free float 168M
Suzhou Zelgen Biopharmaceuticals Co Ltd company profile
- Company name
- Suzhou Zelgen Biopharmaceuticals Co Ltd
- Ticker
- 688266.SHG
- ISIN
- CNE100003RP1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,055
- Fiscal year end
- December
- Address
- No. 209, Chenfeng Road, Kunshan, China, 215300
- Phone
- 86 512 5701 8310
- Website
- zelgen.com
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors. In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. The company's products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
Suzhou Zelgen Biopharmaceuticals Co Ltd management
8- Mr. Zelin ShengChairman of the Board & GM · born 1960
- Mr. Gang HuangCFO & Deputy GM · born 1971
- Ms. Zeqi ShengChief Scientific Officer · born 1964
- Ms. Huiping LuExecutive VP & Director · born 1967
- Mr. Jisheng WuDeputy General Manager · born 1965
- Mr. Binhua LyuDeputy GM, EVP of Chemistry & Director · born 1979
- Ms. Qingping GaoDeputy GM & Board Secretary · born 1977
- Shice ShaoHead of Accounting Department